|
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study. |
|
|
Honoraria - AstraZeneca; BMS; Janssen; Lilly; MSD; Pfizer; Roche; Roche; Takeda |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck; MSD; Pfizer; Roche; Roche; Takeda |
Speakers' Bureau - AstraZeneca; BMS; MSD; Pfizer; Roche; Takeda |
Research Funding - AstraZeneca; Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD; Pfizer; Pierre Fabre (Inst); Roche (Inst); Takeda |
Travel, Accommodations, Expenses - AstraZeneca; BMS; Boehringer Ingelheim; Bristol Myers Squibb Company; Lilly; MSD; Pierre Fabre; Roche; ROCHE; Takeda |
Other Relationship - Pfizer |
|
|
Consulting or Advisory Role - Affini-T Therapeutics; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Foundation Medicine; Gritstone Bio; Instil Bio; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst) |
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation |
|
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb/Medarex; Chemocentryx; Merck; Novartis; Pfizer |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck; Protalix Biotherapeutics; Regeneron; Xenetic Biosciences |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Medarex (Inst); CLS-Therapeutics (Inst); CLS-Therapeutics (Inst); Merck (Inst); Protalix Biotherapeutics (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck |
|
|
Travel, Accommodations, Expenses - Roche (Inst) |
|
Fedor Vladimirovich Moiseenko |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Roche |
Speakers' Bureau - AstraZeneca; BIOCAD; Novartis; Pfizer; Roche; Svixx |
Expert Testimony - Novartis; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca; BIOCAD; Novartis; Pfizer; R-Pharm; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Roche |
Expert Testimony - Bristol-Myers Squibb; Novartis; Sandoz |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche; Sanofi |
|
|
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Janssen; MSD; Pfizer; Roche; Sanofi; Takeda; Viatris |
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; MSD; Roche; Sanofi |
Research Funding - Pfizer (Inst); Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD; Takeda |
|
|
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Berlin-Chemie; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Sanofi/Aventis; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Sanofi/Aventis; Takeda |
Research Funding - Roche Pharma AG |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bristol-Myers Squibb; Lilly; Roche Pharma AG; Takeda |
(OPTIONAL) Uncompensated Relationships - Deutsche Forschungsgemeinschaft; Deutsche Krebsgesellschaft, Arbeitsgemeinschaft Internistische Onkologie; German Society for Pneumology and Respiratory Medicine |
|
|
No Relationships to Disclose |
|
T.Jeroen Jeroen Nicolaas Hiltermann |
Consulting or Advisory Role - BMS (Inst) |
Research Funding - AZD (Inst); BMS (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Ono Pharmaceutical |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Covidien; Illy Lilly Japan; Intuitive Japan; JJ Innovative Medicine; Kyowa Kirin; MSD; Olympus; Ono Pharmaceutical; Pfizer; Stryker; Taiho pharmaceutical; Takeda |
Research Funding - Boehringer Ingelheim; Chugai Pharma; Illy Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical |
|
|
Leadership - Innovent BIOLOGICS, INC |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab |
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche |
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst) |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Incyte |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb Hong Kong |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Honoraria - Brystol-Myers Squibb; IDEOlogy Health; Mark Foundation for Cancer Research; Medscape; Onclive; Peerview; Roche; Society for Immunotherapy of Cancer |
Consulting or Advisory Role - Arrowhead Pharmaceuticals; Bristol Myers Squibb; EMD Serono; Genentech; MedImmune; Merck; Regeneron |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); MedImmune (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; IASLC; IDEOlogy Health; Parker Institute for Cancer Immunotherapy; Society for Immunotherapy of Cancer |